Skip to main content
Contact Us
Subscribe
E-Edition
75°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Novartis Ag ADR
(NY:
NVS
)
111.80
+1.27 (+1.15%)
Official Closing Price
Updated: 7:00 PM EDT, Jul 17, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Novartis Ag ADR
< Previous
1
2
...
26
27
28
29
30
31
32
33
34
...
39
40
Next >
Novartis Has $21B From Roche Stake Sale - Which Company Is On Its M&A Radar?
November 18, 2021
Novartis AG (NYSE: NVS) is getting a massive influx of cash from selling its 20-year stake in Roche Holdings AG (OTC: RHHBY), triggering speculation...
Via
Benzinga
Malaria Diagnostics Market To Make Great Impact In Forecast Period 2019-2026 | Grand View Research, Inc.
November 17, 2021
Via
AB Newswire
See Why Molecular Partners Shares Dropped To 52-Week Low During Tuesday Premarket?
November 16, 2021
Molecular Partners AG (NASDAQ: MOLN) has announced that a planned futility analysis of ensovibep in the Phase 3 ACTIV-3 study has not met the thresholds required to continue...
Via
Benzinga
Johnson & Johnson Pops As It Announces The Biggest Split In Health Care
November 12, 2021
Johnson & Johnson will split its consumer health unit into a publicly traded company.
Via
Investor's Business Daily
Extended Wear Contact Lenses Market to See Huge Growth by 2026: Johnson and Johnson Vision Care, Novartis, Menicon
November 10, 2021
Global Extended Wear Contact Lenses Market Report - Production and Consumption Professional Analysis (Impact of COVID-19) is latest research study released by HTF MI evaluating the market risk side...
Via
SBWire
How To Relieve Stress - New Book, Invisible Stress By Award-Winning Author Sylvia Lafair: Kindle Version to Be Available at No Charge November 3-5, 2021
November 01, 2021
November 01, 2021 -- Sylvia Lafair is the founder of Creative Energy Options (CEOinc), a global business consulting firm and the world's leading authority in Pattern Breakthrough Leadership...
Via
24-7 Press Release
Topics
Lawsuit
Exposures
Financial
Legal
This Company's Innovative Targeted Radiation Therapy Could Offer Potential Hope for Cancer Patients
November 11, 2021
Photo by National Cancer Institute on Unsplash The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a...
Via
Benzinga
Biosimilars Market worth $44.7 billion by 2026 – Key Players are Novartis AG (Switzerland), Pfizer, Inc. (US)
November 10, 2021
Via
AB Newswire
Biosimilars Market Worth $44.7 Billion by 2026 - Size, Industry Trends, Key Players and Forecast
November 10, 2021
Northbrook, IL -- (SBWIRE) -- 11/10/2021 -- Biosimilars Market Research Report Gives in Detailed Analysis of Industry Segments, Opportunities, Growth and Size That Will Help Your Business Grow.
Via
SBWire
Topics
Intellectual Property
Exposures
Intellectual Property
Finance, Legal and Sustainability Professionals at European Listed Companies to Discuss How to Articulate Material ESG Issues
November 10, 2021
SOURCE: IR Magazine
Via
3BL Media
Novartis Dumps Another Bispecific Candidate From Xencor Deal
November 09, 2021
Novartis AG (NYSE: NVS) terminated its ex-US rights to the program dubbed vibecotamab, a bispecific targeting CD123 and CD3 for acute myeloid leukemia. The...
Via
Benzinga
The Daily Biotech Pulse: Double Dose Of Positive Tidings For Merck, Alkermes Slips On Partial Termination Of J&J Licensing Deal, Amgen Migraine Drug Data
November 09, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck Gets Antitrust Nod For Acceleron Deal In Germany, Austria, Announces...
Via
Benzinga
PixelMEDIA and Docmation Continue Focus on Ecommerce with GearsCRM
November 09, 2021
GearsCRM joins Pixel and Docmation to build a combined organization for delivery of a complete ecommerce solution on Salesforce.
Via
PR Leap
The Old Lady Of Threadneedle Street
November 05, 2021
US markets are up on better jobs growth reported for October today.
Via
Talk Markets
+15% CAGR & COVID-19 Impact on Difluprednate Market Can See 451 Million by 2027 Major Novartis, Ajanta Pharma, Sun Pharmaceutical, General Pharmaceuticals, Orchidia
November 05, 2021
This report presents a comprehensive overview, market shares, and growth opportunities of Difluprednate market by product type, application, key manufacturers and key regions and countries.
Via
SBWire
Exposures
COVID-19
Mid-Morning Market Update: Markets Open Higher; US Economy Adds 531,000 Jobs
November 05, 2021
Following the market opening Friday, the Dow traded up 0.84% to 36,429.04 while the NASDAQ rose 0.68% to 16,049.24. The S&P also rose, gaining 0.74% to 4,714.85. The U.S. has...
Via
Benzinga
Topics
Economy
Stocks
Exposures
Economy
US Equities
Why Did Deciphera Stock Plunged 70% Today?
November 05, 2021
Deciphera Pharmaceuticals Inc (NASDAQ: DCPH) stock plunged to a 52-week after announcing disappointing results from the INTRIGUE Phase 3 study of Qinlock in...
Via
Benzinga
Biopharmaceuticals Market Is Set to Experience a Revolutionary Growth in Future
November 05, 2021
Edison, NJ -- (SBWIRE) -- 11/05/2021 -- HTF Market Intelligence added research publication document on Global Biopharmaceuticals Market breaking major business segments and highlighting wider level...
Via
SBWire
Topics
Supply Chain
Exposures
Supply Chain
64 Stocks Moving In Friday's Mid-Day Session
November 05, 2021
Gainers Mainz Biomed B.V. (NASDAQ: MYNZ) shares climbed 198.4% to $14.92. Mainz Biomed priced its initial public offering of 2 million ordinary shares at $5, the middle of the...
Via
Benzinga
Novartis' Iptacopan Meets Primary Endpoint Goal In Rare Kidney Disease Trial
November 04, 2021
Novartis AG (NYSE: NVS) has announced Phase 2 trial data of iptacopan, a selective factor B inhibitor, in patients with C3 glomerulopathy (C3G). In C3G, an overly-active...
Via
Benzinga
Specialty Pharmaceutical Market to Witness Massive Growth by 2028 : Pfizer, Roche, Amgen, AbbVie
November 04, 2021
Stay up-to-date with Specialty Pharmaceutical Market research offered by HTF MI. Check how key trends and emerging drivers are shaping this industry growth.
Via
SBWire
Exposures
COVID-19
Therapeutic Radiopharmaceuticals Market May Set Epic Growth Story : Dongcheng, Q BioMed, Lantheus
November 04, 2021
Stay up-to-date with Therapeutic Radiopharmaceuticals Market research offered by HTF MI. Check how key trends and emerging drivers are shaping this industry growth.
Via
SBWire
Topics
Supply Chain
Exposures
Supply Chain
The Daily Biotech Pulse: Merck's Oral COVID-19 Pill Authorized In UK, Novartis Cashes Out Of Roche, Chimerix Plunges On Data, Evotec IPO
November 04, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck's Oral Antiviral COVID-19 Pill Authorized In UK Merck &...
Via
Benzinga
Exposures
COVID-19
Novartis To Offload Its Stake Back To Roche For $20.7B
November 04, 2021
Novartis AG (NYSE: NVS), a shareholder in Roche Holdings AG (OTC: RHHBY) for more than 20 years, would sell its entire stake, which is nearly one-third voting...
Via
Benzinga
Energize – A First-of-Its-Kind Program to Increase Access to Renewable Energy for Pharmaceutical Suppliers
November 04, 2021
SOURCE: Novartis
Via
3BL Media
Topics
Emissions
Supply Chain
Exposures
Supply Chain
Novartis Inks $1.3B Protein Degradation Deal With UK's Dunad
November 02, 2021
The U.K.-based Dunad Therapeutics has entered a strategic collaboration and license agreement with Novartis AG (NYSE: NVS) to generate orally...
Via
Benzinga
FDA Approves Novartis' Scemblix In Two Chronic Myeloid Leukemia Settings
November 01, 2021
The FDA has approved Novartis AG's (NYSE: NVS) Scemblix (asciminib) for chronic myeloid leukemia (CML) in two distinct indications. The FDA granted...
Via
Benzinga
Exposures
Product Safety
Tuesday Market Coverage
October 26, 2021
Thermo Electron fell on the publication of its social responsibility report today.
Via
Talk Markets
Novartis (NVS) Q3 2021 Earnings Call Transcript
October 26, 2021
NVS earnings call for the period ending September 30, 2021.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Skin Cancer Therapeutics Market to Witness Massive Growth by 2028 : Bristol Myers Squibb, Eli Lilly, Roche
October 28, 2021
Stay up-to-date with Skin Cancer Therapeutics Market research offered by HTF MI. Check how key trends and emerging drivers are shaping this industry growth.
Via
SBWire
Exposures
COVID-19
< Previous
1
2
...
26
27
28
29
30
31
32
33
34
...
39
40
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.